New Drug JPC-2067-B Fights Toxoplasma gondii
Author Information
Author(s): Mui Ernest J., Schiehser Guy A., Milhous Wilbur K., Hsu Honghue, Roberts Craig W., Kirisits Michael, Muench Stephen, Rice David, Dubey J. P., Fowble Joseph W., Rathod Pradipsinh K., Queener Sherry F., Liu Susan R., Jacobus David P., McLeod Rima
Primary Institution: University of Chicago
Hypothesis
JPC-2067-B is an effective treatment for Toxoplasma gondii infections.
Conclusion
JPC-2067-B is highly effective against T. gondii both in vitro and in vivo, showing potential as a less toxic treatment option.
Supporting Evidence
- JPC-2067-B inhibits T. gondii growth in culture with an IC50 of 20 nM.
- JPC-2067-B is more effective than the current standard treatment, pyrimethamine.
- JPC-2067-B is cidal in vitro and effective in vivo against T. gondii tachyzoites.
Takeaway
A new medicine called JPC-2067-B can kill a germ that makes people sick, and it might be safer than older medicines.
Methodology
The study tested the effectiveness of JPC-2067-B against T. gondii in cell cultures and in mice.
Limitations
The study primarily focused on in vitro and animal models, which may not fully predict human responses.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website